Gene Editing Stock in ARKG Gets Buy Rating : vimarsana.com

Investors may want to follow an active biotech ETF, the ARK Genomic Revolution ETF (ARKG), which holds recently buy-rated firm BEAM.

Related Keywords

, Beam Therapeutics , Day Simple Moving Average , Category Average , Factset Segment Average , Etf , Tfs , Xchange Traded Funds , Money , Stock Market , Ark Invest , Markg , Team , Isruptive Technology Channel ,